News|Articles|July 2, 2026

Allergy First Half Recap: 2026

Fact checked by: Tim Smith

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

Allergy and immunology saw significant regulatory momentum in the first half of 2026, headlined by new approvals in allergic fungal rhinosinusitis (AFRS), pediatric hereditary angioedema (HAE), and epinephrine access, alongside pipeline advances in systemic mastocytosis and HAE. Updated international guidelines further refined first-line treatment strategies for pediatric HAE and epinephrine use in anaphylaxis.

Related to this article

November 9th, 2026

ACAAI 2026 Preview: Late-Breakers to Watch Out For

Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.

November 14th, 2026

Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

November 13th, 2026

Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect Analysis

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

November 12th, 2026

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

November 10th, 2026

Allergy Rounds With Dr. Autumn

Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.

November 14th, 2026

Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.